Want to see BWAY full AI Analyst Report?
BWAY Stock Chart & Stats
$14.43
-$0.09(-0.56%)
At close: 4:00 PM EDT
$14.43
-$0.09(-0.56%)
Day’s Range― - ―
52-Week Range$7.14 - $17.40
Previous CloseN/A
Volume84.09K
Average Volume (3M)120.51K
Market Cap
$565.13M
Enterprise Value$567.18
Total Cash (Recent Filing)$62.36M
Total Debt (Recent Filing)$7.13M
Price to Earnings (P/E)58.1
Beta1.54
Next Earnings
Nov 18, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.46
Shares Outstanding40,207,980
10 Day Avg. Volume72,248
30 Day Avg. Volume120,511
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.48
Price to Sales (P/S)3.47
P/FCF Ratio11.06
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$18.50Price Target Upside28.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.32
Revenue Forecast (FY)$68.72M
Bulls Say, Bears Say
Bulls Say
Installed-base And Contract GrowthExpanding system placements and RPO provide a growing commercial base and better revenue visibility. The installed base can support recurring leasing, utilization, consumables, and service revenue as provider adoption deepens.
High-margin Profitable GrowthSustained high gross margins and a 12-quarter positive adjusted EBITDA run indicate improving operating leverage. This strengthens the business model’s ability to fund growth while converting adoption into durable profitability.
Clinical Evidence And Reimbursement ExpansionBroader payer coverage and durable clinical outcomes can reduce adoption barriers for providers and patients. Increasing reimbursement support expands the addressable market and may drive utilization across BrainsWay’s installed base.
Bears Say
Volatile Cash ConversionPositive cash generation is encouraging, but the sharp decline in trailing free cash flow shows that earnings conversion remains inconsistent. Working-capital movements or deal timing could limit internally funded investment during weaker periods.
Rising R&D And G&A CostsHigher clinical-development and corporate spending may be strategically necessary, but it creates pressure on operating leverage. If revenue growth or reimbursement expansion slows, elevated costs could restrain margin sustainability.
Regulatory And Reimbursement UncertaintyExpansion into complex indications depends on regulatory clearance and payer decisions, while local reimbursement policies remain uneven. Delays or limited coverage could postpone commercialization and reduce the impact of promising clinical data.
Brainsway News
BWAY FAQ
What was Brainsway Ltd’s price range in the past 12 months?
Brainsway Ltd lowest stock price was $7.13 and its highest was $17.40 in the past 12 months.
What is Brainsway Ltd’s market cap?
Brainsway Ltd’s market cap is $565.13M.
When is Brainsway Ltd’s upcoming earnings report date?
Brainsway Ltd’s upcoming earnings report date is Nov 18, 2026 which is in 72 days.
How were Brainsway Ltd’s earnings last quarter?
Brainsway Ltd released its earnings results on Aug 12, 2026. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.073 by -$0.003.
Is Brainsway Ltd overvalued?
According to Wall Street analysts Brainsway Ltd’s price is currently Undervalued.
Does Brainsway Ltd pay dividends?
Brainsway Ltd does not currently pay dividends.
What is Brainsway Ltd’s EPS estimate?
Brainsway Ltd’s EPS estimate is 0.09.
How many shares outstanding does Brainsway Ltd have?
Brainsway Ltd has 40,207,980 shares outstanding.
What happened to Brainsway Ltd’s price movement after its last earnings report?
Brainsway Ltd reported an EPS of $0.07 in its last earnings report, missing expectations of $0.073. Following the earnings report the stock price went up 10.814%.
Which hedge fund is a major shareholder of Brainsway Ltd?
Currently, no hedge funds are holding shares in BWAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Brainsway Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.50 (28.21% Upside)
$18.50 (28.21% Upside)
Blogger Sentiment
Bullish
BWAY Sentiment 63%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 51.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $71.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
77.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.33%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Brainsway Ltd
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
BWAY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: the company delivered strong top-line growth (35% YoY), significant margin and profitability expansion (operating income +300% YoY; adjusted EBITDA +141% YoY), increased installed base and RPOs, raised full-year guidance, and presented supportive clinical/reimbursement data (SWIFT durability and PTSD+MDD real-world results). Noted risks relate to increased R&D/G&A spending, dependence on payer adoption and local reimbursement variability, early-stage nature and timing of contributions from minority investments (including Neurolief), and the timing of backlog revenue recognition. Overall, the positives—robust growth, margin expansion, strengthened cash position, and clinical momentum—significantly outweigh the operational and timing risks discussed.View all BWAY earnings summariesBWAY Stock 12 Month Forecast
Average Price Target
$18.50
▲(28.21% Upside)
Technical Analysis
Sanuwave Health
―
Tactile Systems Technology
―
Viemed Healthcare
―
TriSalus Life Sciences
―
NeuroPace
―
Ownership Overview
0.16% Insiders
1.18% Mutual Funds
21.30% Other Institutional Investors
76.73% Public Companies and
Individual Investors